Clinical Trials
> Lung Cancer

CA209370

A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies.

EMR 100070-005

A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer.

EMR 100070-001

A Phase I open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally Multiple/All Tumor Types and expansion to selected indications.

EMR 100070-004

A Phase III open-label, multicenter trial of MSB0010718C versus Docetaxel  in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet.

TO OPEN IN MAY

A Phase III open-label, multicenter trial of Avelumab (MSB0010718C) versus Docetaxel  in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet.

SWOG 1400

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.

PM1183-C-003-14

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS).

E4512

A Phase III Double-Blinded Trial for Surgically Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.